Which is worse: uterine papillary serous carcinomas or carcinosarcomas?

다국어 초록 (Multilingual Abstract)

Objective: It is clear that uterine carcinosarcomas and uterine papillary serous carcinomas (UPSC) have an adverse impact on outcome, but whether carcinosarcomas are worse than UPSC is unclear. The purpose of this study is to compare the pathology, survival, and disease recurrence of patients with carcinosarcomas to patients with UPSC.
Methods: The medical records of patients diagnosed with carcinosarcomas and UPSC between 1996 and 2009 at Samsung Medical Center were retrospectively analyzed. Information from pathology reports, site of relapse, time to recurrence, and death was obtained. The survival analysis was performed using the Kaplan-Meier method.
Results: Thirty seven patients with carcinosarcomas and 38 patients with UPSC were identified during the study period. There was no significant difference in clinical characteristics including age, body mass index, proportion with advanced stage disease, rate of optimal debulking, and adjuvant treatment used. In addition, the pathology showed no significant difference in tumor size, myometrial involvement, lymphovascular invasion, peritoneal cytology, cervical invasion, and lymph node involvement. Patients with carcinosarcomas had similar patterns of relapse as the patients with UPSC. There was no difference in the progression- free and overall survival between the carcinosarcomas and UPSC patients (p=0.804 and p=0.651, respectively).
Conclusion: Patients with carcinosarcomas had similar clinicopathological features compared to the patients with UPSC.

다국어 초록 (Multilingual Abstract)

Objective: It is clear that uterine carcinosarcomas and uterine papillary serous carcinomas (UPSC) have an adverse impact on outcome, but whether carcinosarcomas are worse than UPSC is unclear. The purpose of this study is to compare the pathology, survival, and disease recurrence of patients with carcinosarcomas to patients with UPSC.
Methods: The medical records of patients diagnosed with carcinosarcomas and UPSC between 1996 and 2009 at Samsung Medical Center were retrospectively analyzed. Information from pathology reports, site of relapse, time to recurrence, and death was obtained. The survival analysis was performed using the Kaplan-Meier method.
Results: Thirty seven patients with carcinosarcomas and 38 patients with UPSC were identified during the study period. There was no significant difference in clinical characteristics including age, body mass index, proportion with advanced stage disease, rate of optimal debulking, and adjuvant treatment used. In addition, the pathology showed no significant difference in tumor size, myometrial involvement, lymphovascular invasion, peritoneal cytology, cervical invasion, and lymph node involvement. Patients with carcinosarcomas had similar patterns of relapse as the patients with UPSC. There was no difference in the progression- free and overall survival between the carcinosarcomas and UPSC patients (p=0.804 and p=0.651, respectively).
Conclusion: Patients with carcinosarcomas had similar clinicopathological features compared to the patients with UPSC.

참고문헌 (Reference)

1 Mayall F, "p53 immunostaining suggests that uterine carcinosarcomas are monoclonal" 24 : 211-214, 1994

2 Goff BA, "Uterine papillary serous carcinoma: patterns of metastatic spread" 54 : 264-268, 1994

3 Hamilton CA, "Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers" 94 : 642-646, 2006

4 Vaidya AP, "Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma" 103 : 684-687, 2006

5 McCluggage WG, "Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas" 12 : 687-690, 2002

6 Gal D, "The new International Federation of Gynecology and Obstetrics surgical staging and survival rates in early endometrial carcinoma" 69 : 200-202, 1992

7 Morrow CP, "Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study" 40 : 55-65, 1991

8 Aalders JG, "Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients" 17 : 85-103, 1984

9 Matthews RP, "Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women" 65 : 206-212, 1997

10 Alektiar KM, "Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer" 54 : 79-85, 2002

11 Zelmanowicz A, "Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors" 69 : 253-257, 1998

12 Amant F, "Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer" 98 : 274-280, 2005

13 Ronnett B, "Endometrial carcinoma. In: Kurman R, editor. Blaustein’s pathology of the female genital tract. 5th ed" Springer-Verlag 460-501, 2002

14 Szukala SA, "Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases" 9 : 131-136, 1999

15 Nielsen SN, "Clinicopathologic analysis of uterine malignant mixed mullerian tumors" 34 : 372-378, 1989

16 Silverberg SG, "Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology Group pathologic study of 203 cases" 9 : 1-19, 1990

17 Creasman WT, "Carcinoma of the corpus uteri: FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer" 95 (95): S105-43, 2006

18 Creasman WT, "Carcinoma of the corpus uteri" 6 : 47-86, 2001

19 Jemal A, "Cancer statistics, 2009" 59 : 225-249, 2009

20 Madison T, "Cancer of the corpus uteri in white and black women in Michigan, 1985-1994: an analysis of trends in incidence and mortality and their relation to histologic subtype and stage" 83 : 1546-1554, 1998

21 Sherman ME, "Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus" 98 : 176-186, 2003

22 Bland AE, "A clinical and biological comparison between malignant mixed mullerian tumors and grade 3 endometrioid endometrial carcinomas" 19 : 261-265, 2009